Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease

4 minutes read

Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease

Yupelri™ (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated as a maintenance treatment for chronic obtrusive pulmonary disease (COPD) in adult patients.

Drug Name

Yupelri™ (revefenacin)

Developers

Theravance Biopharma, Mylan

Therapy Class

Nebulised bronchodilator

Product Description

Long-acting muscarinic antagonist

Current Indication

Chronic obtrusive pulmonary disease (COPD)

Yupelri™ is a long-acting muscarinic antagonist indicated for the treatment of chronic obtrusive pulmonary disease in adult patients. Image courtesy of FreeImages.com/Dave Kennard.

COPD is a chronic inflammatory lung condition that causes difficulty in breathing and predisposition to exacerbations and serious illness. Image courtesy of FreeImages.com/Adam Ciesielski.

Yupelri™ contains revefenacin as the active ingredient. Image courtesy of National Center for Biotechnology Information, U.S. National Library of Medicine.

Yupelri^™ (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated as a maintenance treatment for chronic obtrusive pulmonary disease (COPD) in adult patients.

Jointly developed by Theravance Biopharma and Mylan, it is one of the first once-daily, nebulised bronchodilators to be approved by the US Food and Drug Administration (FDA).

The companies submitted the new drug application (NDA) for revefenacin to the FDA in November 2017, which was accepted for review in January 2018. It was approved for the treatment of COPD in adult patients in November 2018.

COPD causes and symptoms

COPD is a chronic inflammatory lung condition that obstructs airflow in the lungs, causes breathing difficulties. It is a progressive life-threatening disease characterised by continuous reduction of airflow.

The condition is the third leading cause of death in the US, affecting approximately 16 million people in the country. COPD is commonly of two types, chronic bronchitis and emphysema.

“COPD is the third leading cause of death in the US, affecting approximately 16 million people.”

Tobacco smoking, air pollution and exposure to second hand smoke, fumes and chemicals in workplaces are the primary causes of the disease. Genetic factors also play a role.

The most common symptoms of the disease are coughing with mucus, shortness of breath, chest tightness and wheezing.

Yupelri’s mechanism of action

Revefenacin is an anticholinergic and demonstrates similar affinity to various subtypes of muscarinic receptors (M1 to M5). It inhibits the M3 receptor present around the airways in the lungs and shows pharmacological effects, causing bronchodilation.

Yupelri^™ is available as a sterile, clear, colourless, aqueous solution of revefenacin. It is an oral inhalation solution available in a unit-dose low-density polyethylene vial for nebulisation by standard jet nebuliser connected to an air compressor, equipped with a mouthpiece. Each vial contains 175mcg/3ml solution.

Clinical trials on Yupelri

The clinical trials for evaluating the safety and efficacy of Yupelri^™was performed in 2,285 COPD patients in two replicate 12-week efficacy studies and one 52-week long-term open-label active control clinical trial. The 12-week efficacy studies enrolled 1,229 patients, while the 52-week safety study enrolled 1,055 patients.

Out of 1,229 patients enrolled for the two 12-week placebo-controlled trials, 395 patients received once-daily 175 micrograms (mcg) of revefenacin. The doses were administered through PARI LC^® Sprint Reusable Nebuliser, which is a standard jet nebuliser. The mean nebulisation time of the drug was eight minutes. The primary endpoint of the studies was a change from baseline in trough (predose) forced expiratory volume in one second (FEV₁) at day 85.

The patients receiving revefenacin demonstrated noteworthy improvement in lung function compared with those on placebo. After 12 weeks, statistically significant improvements were found in trough FEV₁ and in overall treatment effect on trough FEV_1.

The most common adverse events noticed in patients during the trials were coughing, nasopharyngitis, upper respiratory tract infection, headache and back pain.

Out of the 1,055 patients enrolled in the 52-week study, 335 patients received 175mcg of Yupelri^™ once daily and 356 patients received tiotropium 18mcg once daily.

The adverse events in the 52-week long-term safety study were almost similar to those observed in the 12-week studies.

Reference

Heo YA. Revefenacin: first global approval. Drugs. 2019 Jan;79(1):85-91.
Clark CM, Jacobs DM, Sethi S. Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine. 2020 Mar 3;14(3):239-47.
Bourdet DL, Yeola S, Hegde SS, Colson PJ, Barnes CN, Borin MT. Revefenacin absorption, metabolism, and excretion in healthy subjects and pharmacological activity of its major metabolite. Drug Metabolism and Disposition. 2020 Dec 1;48(12):1312-20.
Donohue JF, Mahler DA, Sethi S. Revefenacin: a once-daily, long-acting bronchodilator for nebulized treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2019 Dec 19:2947-58.
Zhang J, Xie Y, Kwong JS, Ge L, He R, Zheng W, Han J, Zhang R, Zhao H, He Y, Li X. The efficacy and safety of revefenacin for the treatment of chronic obstructive pulmonary disease: a systematic review. Frontiers in Pharmacology. 2021 Oct 20;12:667027.
Borin MT, Barnes CN, Darpo B, Pendyala S, Xue H, Bourdet DL. Revefenacin, a long‐acting muscarinic antagonist, does not prolong QT interval in healthy subjects: results of a placebo‐and positive‐controlled thorough QT study. Clinical Pharmacology in Drug Development. 2020 Jan;9(1):130-9.
LeMaster WB, Witenko CJ, Lacy MK, Olmsted AW, Moran EJ, Mahler DA. Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2024 Dec 31:2299-308.
Li F, Yang J. Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology. 2019 Apr 3;12(4):293-8.
Siler TM, Moran EJ, Barnes CN, Crater GD. Safety and efficacy of revefenacin and formoterol in sequence and combination via a standard jet nebulizer in patients with chronic obstructive pulmonary disease: a phase 3b, randomized, 42-day study. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2020 Mar 13;7(2):99.
Hvisdas C. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy. 2021 Jul 1;78(13):1184-94.
Wilkinson J, Tutalo R. Revefenacin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease. American Family Physician. 2020 Jan 15;101(2):121-2.